NR565 Week 4 Midterm Exam - Chamberlain University

Explanation:

Correct Answer: (A) They act on the distal convoluted tubule to inhibit sodium reabsorption

Thiazide diuretics work specifically at the distal convoluted tubule of the nephron, where they inhibit sodium and chloride reabsorption. This action promotes increased excretion of sodium and water, resulting in a diuretic effect that is commonly used to manage hypertension and edema.

Why Other Options are Incorrect:

B. They increase calcium excretion, leading to hypocalcemia Thiazide diuretics actually decrease calcium excretion, promoting calcium reabsorption, which can lead to hypercalcemia rather than hypocalcemia.

C. They are effective even in patients with severe renal impairment Thiazide diuretics generally lose effectiveness in patients with severe renal impairment, as reduced kidney function limits their ability to act on the nephron.

D. They cause potassium retention and are considered potassium-sparing Thiazide diuretics cause potassium loss/wasting and are not classified as potassium-sparing; this describes agents like spironolactone instead.

Explanation:

Correct Answer: (C) The β blocker helps suppress nitroglycerin-induced tachycardia

Nitroglycerin causes vasodilation, which can trigger reflex tachycardia as the body compensates for the resulting drop in blood pressure. Beta blockers counteract this reflex tachycardia by blunting the sympathetic nervous system's compensatory increase in heart rate, making the combination beneficial in managing conditions like angina while minimizing this unwanted cardiovascular side effect.

Why Other Options are Incorrect:

A. The β blocker enhances the vasodilatory effects of nitroglycerin Beta blockers do not enhance nitroglycerin's vasodilatory action; their primary contribution is countering reflex tachycardia, not augmenting vasodilation.

B. The β blocker prevents nitroglycerin metabolism by the liver Beta blockers do not act on nitroglycerin's hepatic metabolism; this is not the mechanism behind the beneficial combination.

D. The combination increases blood pressure to prevent hypotension Both drugs can lower blood pressure, and the combination is not intended to increase blood pressure; the rationale relates specifically to heart rate control, not blood pressure elevation.

Explanation:

Correct Answer: (C) Colchicine (Colcrys) is used both to treat acute gout attacks and to prevent future flareups

Colchicine has a dual role in gout management: it is used at higher doses to treat acute gout flares by reducing inflammation, and at lower prophylactic doses to prevent future flareups, particularly during the initiation of urate-lowering therapy when flare risk is temporarily increased. This dual indication distinguishes it from urate-lowering agents.

Why Other Options are Incorrect:

A. Colchicine (Colcrys) is only approved for use during acute gouty episodes This is incomplete, as colchicine is also approved and commonly used for prophylaxis against future gout flares, not just acute treatment.

B. Colchicine (Colcrys) is the preferred first-line treatment for gout due to its minimal side effects Colchicine has a narrow therapeutic index and notable gastrointestinal side effects, so it is not considered to have minimal side effects, and NSAIDs or corticosteroids are often preferred first-line for acute attacks.

D. Colchicine (Colcrys) lowers uric acid levels by increasing renal excretion Colchicine does not lower uric acid levels at all; it works by reducing inflammation and leukocyte activity, unlike uricosuric agents which do increase renal excretion of uric acid.

Explanation:

Correct Answer: (C) The patient is in a protracted withdrawal phase and would benefit from supportive, non-opioid symptom management

Protracted withdrawal syndrome can occur weeks after acute opioid withdrawal has resolved, presenting with lingering symptoms such as insomnia, irritability, fatigue, and mild gastrointestinal discomfort, even in the absence of cravings or acute withdrawal signs. Management focuses on supportive, non-opioid strategies to address these residual symptoms while supporting the patient's continued recovery.

Why Other Options are Incorrect:

A. The patient is experiencing rebound euphoria and should be referred for mental health evaluation Rebound euphoria is not a recognized clinical phenomenon in this context, and the symptoms described are consistent with protracted withdrawal rather than a mood-related euphoric state.

B. The patient is demonstrating signs of benzodiazepine withdrawal and should be screened for polysubstance use There is no indication in the scenario of benzodiazepine use, and the symptoms described align with protracted opioid withdrawal rather than a separate substance's withdrawal syndrome.

D. These symptoms reflect opioid tolerance and suggest a need for reinstating opioid therapy Tolerance refers to needing more of a substance for the same effect, which is not relevant here since the patient has discontinued opioids; reinstating opioid therapy is not indicated for protracted withdrawal symptoms.

Explanation:

Correct Answer: (A) Pain location, type, functional impact, and contributing psychological factors should be evaluated

A comprehensive initial pain assessment before prescribing opioids requires evaluating multiple dimensions of the patient's pain experience, including its location, type (such as nociceptive or neuropathic), how it affects functional ability, and any contributing psychological or social factors. This thorough, multidimensional assessment ensures appropriate treatment planning and helps identify patients who may be at higher risk for opioid-related complications.

Why Other Options are Incorrect:

B. It is sufficient to document the pain intensity score using a 0-10 scale A numeric pain score alone provides insufficient information for comprehensive opioid prescribing decisions, missing critical context about the nature and impact of the pain.

C. A physical exam is not necessary if the patient describes the pain clearly A physical examination is an essential component of a thorough pain assessment and should not be omitted regardless of how well the patient can verbally describe their symptoms.

D. Pain relief alone should be the primary goal of opioid therapy Functional improvement, not pain relief alone, is considered a key goal of opioid therapy for chronic pain, reflecting a broader, more meaningful treatment outcome.

Explanation:

Correct Answer: (D) Faster rate of dissolution leading to quicker absorption

A rapidly dissolving tablet breaks down and releases its active drug more quickly than an extended-release formulation, which is specifically designed to release medication slowly over time. This faster dissolution rate allows the drug to become available for absorption into the bloodstream more quickly, resulting in a faster onset of action compared to the extended-release form.

Why Other Options are Incorrect:

A. Faster blood flow in the liver compared to peripheral tissues Hepatic blood flow relates to drug metabolism after absorption, not to the initial dissolution and absorption rate that differentiates these two formulations.

B. Increased lipid solubility in extended-release drugs Extended-release formulations are not defined by increased lipid solubility; their delayed release is due to specific formulation design, not a change in the drug's inherent lipid solubility.

C. Larger surface area of the stomach compared to the intestine The intestine actually has a much larger absorptive surface area than the stomach, and this is not the differentiating factor between the two formulation types described.

Explanation:

Correct Answer: (B) It reduces intracellular sodium and calcium without significantly affecting heart rate or blood pressure

Ranolazine works through a unique mechanism distinct from other antianginal agents by inhibiting the late sodium current in cardiac cells, which subsequently reduces intracellular calcium overload. This mechanism improves myocardial relaxation and reduces oxygen demand without producing the hemodynamic effects, such as changes in heart rate or blood pressure, that are typically seen with beta blockers, calcium channel blockers, or nitrates.

Why Other Options are Incorrect:

A. It primarily reduces heart rate and blood pressure within minutes of taking it Ranolazine's defining characteristic is that it does not significantly affect heart rate or blood pressure, unlike other antianginal agents, making this option contrary to its actual mechanism.

C. It directly increases myocardial oxygen supply and reduces peripheral vascular resistance Ranolazine's mechanism relates to intracellular sodium and calcium regulation rather than directly increasing oxygen supply or reducing vascular resistance.

D. It causes coronary vasodilation to relieve anginal pain in combination with nitroglycerin Ranolazine does not work through a vasodilatory mechanism; this describes the action of nitrates, not ranolazine's unique sodium/calcium-based mechanism.

Explanation:

Correct Answer: (B) Administer ezetimibe 4 hours after the sequestrant

Bile acid sequestrants can bind to and reduce the absorption of ezetimibe if taken together. To minimize this interaction, ezetimibe should be administered either at least 2 hours before or 4 hours after the bile acid sequestrant, allowing adequate time for the sequestrant to pass through the GI tract before ezetimibe is given, ensuring proper absorption of both medications.

Why Other Options are Incorrect:

A. Administer sequestrant 1 hour before ezetimibe A 1-hour separation is insufficient to prevent the sequestrant from binding ezetimibe and reducing its absorption.

C. Administer both drugs separately at bedtime Giving both medications at bedtime without adequate time separation would not prevent the interaction, since the timing gap, not just the time of day, is what matters.

D. Administer ezetimibe and sequestrant simultaneously Taking these medications simultaneously would maximize, not minimize, the interaction, significantly reducing ezetimibe's absorption and effectiveness.

Explanation:

Correct Answer: (A) To alert providers to serious or life-threatening risks and strategies to reduce harm

A boxed warning, also known as a "black box warning," is the FDA's most serious labeling requirement, used to highlight significant risks of serious adverse effects, including life-threatening reactions, associated with a medication. It also typically includes guidance on strategies to mitigate these risks, ensuring prescribers are fully informed before initiating therapy.

Why Other Options are Incorrect:

B. To indicate that the drug is experimental and not yet FDA-approved A boxed warning applies to FDA-approved medications with known serious risks, not to experimental or unapproved drugs.

C. To inform patients that the drug may cause mild, temporary side effects Boxed warnings are reserved for serious or life-threatening risks, not mild or temporary side effects, which would be addressed in standard labeling sections.

D. To highlight that the medication is only available over the counter A boxed warning has no relation to a medication's prescription versus over-the-counter status; it specifically addresses serious safety concerns.